Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 11, 2022 22:05 ET | Source: IN8bio, Inc

IN8bio Announces Pricing of $10.25 Million Underwritten Public Offering of Common Stock

NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell...
July 27, 2022 07:00 ET | Source: IN8bio, Inc

IN8bio Observes Durable Morphologic Complete Responses in Ongoing Phase 1 Clinical Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in High-Risk Leukemia Patients

All three patients from the first cohort of high-risk relapsed acute-myeloid leukemia (AML) patients dosed to-date with INB-100 remain alive and progression-free after at least one year.Patients...
July 21, 2022 07:00 ET | Source: IN8bio, Inc

Newly Issued European Patent Broadens IN8bio’s Drug Resistant Immunotherapy (DRI) Platform

European patent covers any genetic modification conveying chemotherapy resistance to immune cell types, including gamma-delta T cells and now natural killer (NK) cellsPatent portfolio broadly covers...
July 12, 2022 08:00 ET | Source: IN8bio, Inc

IN8bio Appoints Kenneth R. LaMontagne, Ph.D., to Lead Business Development

NEW YORK, July 12, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell...
June 30, 2022 16:15 ET | Source: IN8bio, Inc

IN8bio to Present at July Investor and Scientific Conferences

NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell...
June 08, 2022 08:00 ET | Source: IN8bio, Inc

IN8bio Announces Presentation at Jefferies Global Healthcare Conference and Additional June Investor and Scientific Conferences

NEW YORK, June 08, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell...
June 06, 2022 07:00 ET | Source: IN8bio, Inc

IN8bio Announces Positive Glioblastoma Multiforme (GBM) Clinical Updates from the INB-200 Phase 1 Trial Presented at ASCO 2022

100% of dosed patients have exceeded both median and expected progression free survival (PFS). Two patients, to date, having exceeded their expected overall survival (OS). An unmethylated GBM patient...
May 17, 2022 07:00 ET | Source: IN8bio, Inc

IN8bio Announces Data Emerging from its Recently Unveiled Gamma-Delta T cell “Off-the-Shelf” Induced Pluripotent Stem Cell Platform

IN8bio recently unveiled expansion of its DeltEx gamma-delta T cell platform capabilities to include induced pluripotent stem cells (iPSCs).Yesterday, at the American Society for Gene & Cell...
May 12, 2022 08:00 ET | Source: IN8bio, Inc

IN8bio Reports First Quarter 2022 Financial Results and Provides Corporate Update

Phase 1 clinical trial of INB-100 in leukemia patients and INB-200 in newly diagnosed glioblastoma multiforme (GBM) patients continue to generate encouraging data.INB-100 patient update at European...
May 05, 2022 08:00 ET | Source: IN8bio, Inc

IN8bio Unveils Induced Pluripotent Stem Cell (iPSC) Platform at ASGCT 25th Annual Meeting

NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of gamma-delta T cell therapies, today...